Tvardi Q1 net loss narrows to $6.8 million

Tvardi Therapeutics Inc.

Tvardi Therapeutics Inc.

TVRD

0.00
  • Tvardi Therapeutics posted a Q1 net loss of USD 6.8 million, narrowing from USD 9.6 million a year earlier; net loss per share improved to USD (0.73) from USD (3.72).
  • R&D expenses climbed to USD 4.9 million from USD 3.1 million, while G&A costs rose to USD 2.1 million from USD 1.2 million.
  • Cash, cash equivalents and short-term investments fell to USD 25 million at March 31 from USD 30.8 million at Dec. 31; cash runway expected to fund operations through clinical readouts into Q4 2026.
  • Topline data from TTI-109 Phase 1 healthy volunteer study expected in June, with clinical development strategy to be announced based on results; TTI-101 Phase 1b/2 hepatocellular carcinoma topline data targeted for 2H 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080700PRIMZONEFULLFEED9716251) on May 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.